Skip to content
Santhera & ReveraGen Logo

Santhera and ReveraGen: Positive Topline Results with Vamorolone (at 48 Weeks)

November 30, 2021

Defeat Duchenne Canada is pleased to provide the latest update from Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. regarding the completion of the 48-week VISION-DMD study:

The 48-week top-line data readout for vamorolone shows that the statistically robust efficacy demonstrated at 24-weeks is maintained across multiple efficacy endpoints at 48 weeks. In addition, vamorolone treatment at both doses (2 and 6 mg/kg/day) reversed the growth impairment observed during prednisone treatment and were associated with fewer adverse events, including those associated with corticosteroid use.

Defeat Duchenne Canada has granted $1 million to support a clinical trial of vamorolone in Canada and is expected to enrol the first patients early in 2022.

Click here to read Santhera’s latest letter for the Duchenne community:

Click here to read the full press release:

Related Articles